Head-to-head · WeighScore
CoreAge Rx vs MyStart Health
The verdict
CoreAge Rx takes it — 91.8/100 to 67.1/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 91.8/100 (A−).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | CoreAge Rx | MyStart Health |
|---|---|---|
| WeighScore | 91.8/100 | 67.1/100 |
| Grade | A− | C |
| Scorecard rank | #1 | #168 |
| Semaglutide | $149/mo | $299/mo (all doses, compounded) |
| Tirzepatide | $349/mo | $299/mo (all doses, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #1 · A−
Strengths
- Flat all-in price with no month-two step-up
- Semaglutide and tirzepatide on one account
- All 50 states, LegitScript-verified
Where it loses points
- Not the cheapest sticker price
- Compounded only
- Pharmacy partner not yet publicly named
Graded #168 · C
Strengths
- Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
- Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- 24/7 care team access with unlimited clinician messaging included
- LegitScript certified
- Clear Section 503A compounding disclosure on every landing page
Where it loses points
- Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
- Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
- Very new company (incorporated May 2024) with a limited track record
- Pharmacy partners not named, so 503A compliance can't be independently verified
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.